N/A N=21 Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients
Spinocerebellar Ataxias · Tai Chi
Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
Spinocerebellar Ataxia
Primary: Percent Change From Baseline to Post Treatment on the Scale for the Assessment and Rating of Ataxia (SARA) — -25.9; -27.8 percentage change — p=0.29
N/A N=21 Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Ataxia, Cerebellar · Cerebellar Ataxia · Spinocerebellar Ataxias
Primary: Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline — 53.0; 52.7; 43.0; 52.1 units on a scale — p=<0.001
Phase 3 N=141 Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Spinocerebellar Ataxias · Spinocerebellar Ataxia Genotype Type 1 · Spinocerebellar Ataxia Genotype Type 2
Primary: Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8 — -0.810; -1.059 score on a scale — p=0.519
N/A N=62 Training in Ataxia - Individuals With Degenerative Cerebellar Diseases
Cerebellar Ataxia
Primary: Change in Assessment and Rating of Ataxia (SARA) Score — -2.4; -0.9; -1.5; -0.2 score on a scale
N/A N=20 Dalfampridine and Gait in Spinocerebellar Ataxias
Spinocerebellar Ataxias Type 1 · Spinocerebellar Ataxias Type 2 · Spinocerebellar Ataxias Type 3
Primary: Change in Timed 25 Feet Walking Test (T25FW) — 23.7; 24.4; -1.1; -0.3 second — p=>0.05
N/A N=4 Effects of High Intensity Stepping Training on Gait in Patients With Ataxia
Cerebellar Ataxia
Primary: Walking Speed in Meters Per Second as Assessed by the 10 Meter Walk Test(10MWT) — 0.13; 0.60 meters per second
Phase 2 N=22 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients
Nervous System Disorder · Genetic Syndrome
Primary: Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population — -2.2; -3.4; -4.0…
Phase 2 N=67 Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
Friedreich Ataxia
Primary: Change From Baseline in the Inverse Time to Complete the 9-Hole Peg Test (9-HPT-1) — 0.00038; -0.00017; -0.00032 1/seconds — p=>0.999
N/A N=21 Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia
Cerebellar Ataxia · Spinocerebellar Ataxias · Cerebellar Degeneration
Primary: Change in Overt Tapping Accuracy as Assessed by Finger Tapping to a Flashing Cue at 1Hz Speed — .00141488 taps per second
Phase 2 N=10 (+) Epicatechin to Treat Friedreich's Ataxia
Friedreich's Ataxia
Primary: Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score — 55.0 score on a scale — p=0.336
Phase 2 N=22 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
Friedreich Ataxia
Primary: Creatine Rephosphorylation Rate Post Exercise — 0.024; 0.029; 0.022; 0.029 pH per second — p=0.9133
N/A N=8 Postural Stability in Cervical Spinal Myelopathy
Cervical Spondylotic Myelopathy
Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters
N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants
Phase 2 N=10 Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome
Fragile X Tremor/Ataxia Syndrome
Primary: FXTAS Rating Scale Score — 45.8 score on a scale
Phase 4 N=1 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
Friedreich Ataxia
Primary: International Cooperative Ataxia Rating Scale (ICARS) — 39; 30; 47; 46 units
N/A N=40 Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study
Scleroderma · Systemic Sclerosis
Primary: Eligibility: Number of Patients in the SPIN Cohort Who Meet the Cut-off Thresholds for Eligibility — 24; 16 Participants
Phase 2 N=94 Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Safety Labs
N/A N=108 Neurology Measures in FA Children
Friedreich Ataxia
Primary: Change in mFARS (Modified Friedreich's Ataxia Rating Scale) Score — 2.9; 4.9; 7.7; 2.2 units on a scale
Phase 3 N=176 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Nervous System Disease · Genetic Syndrome
Primary: Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS) — 0.8; 1.0; 2.3 score on a scale — p=0.0847
Phase 2 N=12 Interferon Gamma-1b in Friedreich Ataxia (FRDA)
Friedreich Ataxia
Primary: Change in Whole Blood Frataxin Levels — -1.5 percentage of baseline frataxin level — p=0.027
N/A N=53 Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
Spinal Muscular Atrophy (SMA)
Primary: Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) — 36.06; 88.47; 40.54; 89.44 scores on a scale
N/A N=94 Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
Fragile X-Associated Tremor/Ataxia Syndrome · Fragile X Premutation Carriers
Primary: Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II) — 17.44; 16.12; 15.66; 15.72 units on a scale
Phase 3 N=22 Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
SMA - Spinal Muscular Atrophy · Gene Therapy
Primary: Achievement of Independent Sitting for at Least 30 Seconds — 13 Participants — p=<0.0001
N/A N=11 The Role of Cerebellar Hyperactivity in Parkinson's Disease
Parkinson's Disease
Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)
Phase 3 N=232 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients
Friedreich's Ataxia
Primary: Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52 — 1.6; 1.7; 1.2; 1.1 units on a scale
Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
N/A N=15 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
Hereditary Spastic Paraplegia · Adrenomyeloneuropathy
Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds
Phase 2 N=38 CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I
Spinal Muscular Atrophy Type I
Primary: Laboratory Safety Data
Phase 2 N=19 A First in Human Study of RT001 in Patients With Friedreich's Ataxia
Friedreich's Ataxia
Primary: Number of Patients With Adverse Events — 5; 2; 5; 2 participants